WO2022143740A8 - A3腺苷受体激动剂及其制备方法和用途 - Google Patents

A3腺苷受体激动剂及其制备方法和用途 Download PDF

Info

Publication number
WO2022143740A8
WO2022143740A8 PCT/CN2021/142384 CN2021142384W WO2022143740A8 WO 2022143740 A8 WO2022143740 A8 WO 2022143740A8 CN 2021142384 W CN2021142384 W CN 2021142384W WO 2022143740 A8 WO2022143740 A8 WO 2022143740A8
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine
activity
compounds
series
receptor agonists
Prior art date
Application number
PCT/CN2021/142384
Other languages
English (en)
French (fr)
Other versions
WO2022143740A1 (zh
Inventor
胡崇波
叶进启
潘姝花
胡宁
潘婷婷
赵龙
陈正树
孙三兴
Original Assignee
浙江春禾医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 浙江春禾医药科技有限公司 filed Critical 浙江春禾医药科技有限公司
Priority to AU2021413448A priority Critical patent/AU2021413448A1/en
Priority to JP2023540498A priority patent/JP2024502068A/ja
Priority to KR1020237023189A priority patent/KR20230125800A/ko
Priority to CN202180088308.4A priority patent/CN116783196A/zh
Priority to CA3203676A priority patent/CA3203676A1/en
Priority to US18/270,117 priority patent/US20240116975A1/en
Priority to EP21914472.2A priority patent/EP4273153A4/en
Publication of WO2022143740A1 publication Critical patent/WO2022143740A1/zh
Publication of WO2022143740A8 publication Critical patent/WO2022143740A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

提供了一种对A3腺苷受体活性既有调节或激动作用的化合物，该系列化合物的制备方法，该系列化合物的药物组合物，以及该系列化合物的医药用途。该系列化合物可以作为高效的A3腺苷受体激动剂，具有抗肿瘤、抗炎、止痛、神经保护、心肌防护、眼疾治疗和抗感染等多种药理活性。
PCT/CN2021/142384 2020-12-29 2021-12-29 A3腺苷受体激动剂及其制备方法和用途 WO2022143740A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2021413448A AU2021413448A1 (en) 2020-12-29 2021-12-29 Adenosine a3 receptor agonists, preparation methods and uses thereof
JP2023540498A JP2024502068A (ja) 2020-12-29 2021-12-29 Ａ３アデノシン受容体アゴニスト及びその調製方法と用途
KR1020237023189A KR20230125800A (ko) 2020-12-29 2021-12-29 A3 아데노신 수용체 작용제 및 이의 제조 방법과 용도
CN202180088308.4A CN116783196A (zh) 2020-12-29 2021-12-29 A3腺苷受体激动剂及其制备方法和用途
CA3203676A CA3203676A1 (en) 2020-12-29 2021-12-29 Adenosine a3 receptor agonists, preparation methods and uses thereof
US18/270,117 US20240116975A1 (en) 2020-12-29 2021-12-29 Adenosine a3 receptor agonists, preparation methods and uses thereof
EP21914472.2A EP4273153A4 (en) 2020-12-29 2021-12-29 ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011601817 2020-12-29
CN202011601817.6 2020-12-29

Publications (2)

Publication Number Publication Date
WO2022143740A1 WO2022143740A1 (zh) 2022-07-07
WO2022143740A8 true WO2022143740A8 (zh) 2023-07-13

Family

ID=82260231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/142384 WO2022143740A1 (zh) 2020-12-29 2021-12-29 A3腺苷受体激动剂及其制备方法和用途

Country Status (8)

Country Link
US (1) US20240116975A1 (zh)
EP (1) EP4273153A4 (zh)
JP (1) JP2024502068A (zh)
KR (1) KR20230125800A (zh)
CN (1) CN116783196A (zh)
AU (1) AU2021413448A1 (zh)
CA (1) CA3203676A1 (zh)
WO (1) WO2022143740A1 (zh)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002604A1 (en) * 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) * 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1469864A1 (en) * 2002-01-25 2004-10-27 Muscagen Limited Compounds useful as a-3 adenosine receptor agonists
CA2609117A1 (en) * 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0607947D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic Compounds
WO2008156513A2 (en) * 2007-03-29 2008-12-24 University Of Connecticut Methods to protect skeletal muscle against injury
TW202227095A (zh) * 2016-01-08 2022-07-16 美商阿克思生物科學有限公司 胞外5'-核苷酸酶之調節劑及其用途
EP3600273A4 (en) * 2017-03-31 2021-01-20 Peloton Therapeutics, Inc. CD73 INHIBITORS AND THEIR USES
WO2020247546A1 (en) * 2019-06-03 2020-12-10 Biointervene, Inc. Adenosine analogs for the treatment of disease

Also Published As

Publication number Publication date
CN116783196A (zh) 2023-09-19
EP4273153A1 (en) 2023-11-08
CA3203676A1 (en) 2022-07-07
KR20230125800A (ko) 2023-08-29
JP2024502068A (ja) 2024-01-17
WO2022143740A1 (zh) 2022-07-07
AU2021413448A1 (en) 2023-07-20
EP4273153A4 (en) 2024-05-08
US20240116975A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
MX2019013954A (es) Inhibidores covalentes de kras.
MX2019009187A (es) Compuesto de quinazolina.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2020000268A (es) Agonista de fxr.
MX2022006475A (es) Compuestos triciclicos sustituidos.
JOP20200281A1 (ar) مركبات أريل غير متجانسة رباعية الحلقة
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
WO2021055728A8 (en) Small molecule inhibitors of kras g12c mutant
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
WO2021009676A8 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2021012105A (es) Compuestos de pirrol.
MX2021007247A (es) Derivados de rapamicina.
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21914472

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3203676

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023540498

Country of ref document: JP

Ref document number: 202180088308.4

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 20237023189

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021413448

Country of ref document: AU

Date of ref document: 20211229

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021914472

Country of ref document: EP

Effective date: 20230731